NEW YORK, Feb. 3 (GenomeWeb News) - Genome Therapeutics has set a price of $5.25 per share for the sale of up to 16.8 million shares of its common stock, the company said today.

The offering will fund the pending acquisition of Genesoft Pharmaceuticals, which was approved by the shareholders of both firms yesterday. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.